Updated on 10 December 2012
The product is exported in bulk from Debio Recherche Pharmaceutique
Singapore: Dr. Reddy's Laboratories has launched Pamorelin LA in India for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.
Under the terms of the agreement, Dr. Reddy's acquired exclusive marketing and sales rights for Pamorelin LA Depot in India. The product is exported in bulk from Debio Recherche Pharmaceutique. Pamorelin LA will be made available primarily to urologists and oncologists across India.
Debiopharm Group, a Swiss-based global biopharmaceutical group of companies, is focused on the development of prescription drugs that target unmet medical needs and companion diagnostics.
"We recognise the need for prostate cancer treatment in India and are thrilled to have the opportunity to bring Pamorelin LA to Indian patients," said Mr Rolland-Yves Mauvernay, president and founder of Debiopharm Group. "This major step enables us to implement our strategy in one of the most important markets in Asia. This is only the logical continuation to a harmonious working relationship shared with Dr. Reddy's over the years."